As reported on Business Wire, Alkermes plc has initiated a global phase 3 clinical development program to evaluate alixorexton, an investigational oral therapy for people living with narcolepsy type 1…
The American Nutrition Association (ANA) has announced a collaborative initiative with Jazz Pharmaceuticals designed to advance evidence-based nutritional education for individuals living with narcolepsy and idiopathic hypersomnia (IH), sleep disorders…
Excessive daytime sleepiness (EDS) is more than just feeling tired—it can be a debilitating symptom of two distinct neurological disorders: hypersomnia and narcolepsy. While both conditions share the hallmark of…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
In 2021, approximately 37 people per every 100,000 were diagnosed with idiopathic hypersomnia (IH), a neurological disorder characterized by excessive sleepiness and excessive daytime sleepiness. This amounts to roughly…
As many people within the rare disease community know, a rare disease diagnosis can come with a significant financial burden. Additionally, the costs, treatments, equipment, and other needs are not…
Previously approved for the treatment of narcolepsy, pitolisant (marketed under the brand name Wakix) may soon be leveraged for another rare condition: idiopathic hypersomnia (IH). Pitolisant is a histamine 3…
In the United States, the FDA grants Orphan Drug designation to drugs or biologics intended to treat, diagnose, or prevent rare diseases or conditions. A rare disease is one…
Orphan Drug designation is typically granted to drugs or biologics intended to treat, prevent, or diagnose rare diseases; in the United States, these are conditions affecting under 200,000 Americans. Drug…
In a news release from April 2021, biopharmaceutical company Jazz Pharmaceuticals, Inc. ("Jazz") shared that the FDA accepted its supplemental New Drug Application (sNDA) for review in relation to Xywav,…
In late March 2021, the Hypersomnia Foundation and biopharmaceutical company Jazz Pharmaceuticals, Inc. ("Jazz") partnered up to launch the "I Have IH" campaign. The campaign is designed to raise awareness…
2326 words (source) vs. 503 words (mine) - 6% match Near the start of October, global biopharmaceutical company Jazz Pharmaceuticals ("Jazz") announced positive safety and efficacy data from their Phase…
The HF Educational Meeting Seattle, Oregon The conference will be an opportunity for patient families and medical experts to meet and learn about the latest in idiopathic research. Additionally, families…
A study has found that daytime sleepiness and attention may be correlated in people with narcolepsy and hypersomnia, with patients who self-report feeling more sleepy also being more likely to…
A new study looking at a test used to diagnose narcolepsy has found that it often produces inconsistent results for the same patients, reports Sleep Review. This highlights a current…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
